Business Wire

Orca Security Offers Best-in-Class Approach to Secure Cloud-Native Applications, Expanding with ThreatOptix’s Agent-Based Runtime Protection

21.2.2023 14:00:00 EET | Business Wire | Press release

Share

Orca Security, the pioneer of agentless cloud security, today announced that the Orca Cloud Security Platform will include ThreatOptix’s agent-based runtime protection and enforcement for cloud-native applications, including virtual machines, containers, and Kubernetes applications. While Orca remains committed to agentless cloud security, this new capability builds on Orca's industry leadership in delivering the most comprehensive coverage and visibility across the cloud estate and offers customers a choice in how they want to secure their applications.

New capabilities from ThreatOptix, whose technology provides comprehensive Linux security with an emphasis on cloud workload protection, will enhance the runtime detection and enforcement within the Orca Cloud Security Platform. The new features in the Orca Platform will be delivered via a strategic partnership with ThreatOptix, where all agent deployments and policy management, as well as data, will be fully integrated into the Orca Platform and sold as a single platform.

Security teams have many challenges in securing modern workloads, including vulnerability management, compliance monitoring, and advanced threat detection and prevention. Orca has been solely focused on delivering best-in-breed agentless capabilities to address these concerns. Yet there are specific mission critical applications where organizations may require an agent for advanced runtime protection and enforcement.

According to Enterprise Strategy Group*, “The growing footprint of Linux-based workloads, both virtual machine instances and application containers, has become a more prominent facet of the attack surface. Because these assets are temporal, they are often not running when security analysts are conducting investigations. As such, capturing system activity with an EDR offering that is purpose-built for Linux workloads is required.”

“At Orca Security, we have a mission to continually innovate cloud security and push the limits of what’s possible to be your key partner for securing the entirety of your cloud environments now and in the future,” said Avi Shua, CEO and co-founder of Orca Security. “As we expand our Cloud Security Platform, we are strategically partnering with ThreatOptix due to their core focus on delivering runtime protection and enforcement for cloud-native applications.”

ThreatOptix was founded by Ehud (“Udi”) Shamir and Sameet Mehta. Udi co-founded the XDR pioneer SentinelOne, where Sameet served as CFO, and both bring years of experience in workload runtime protection.

“At ThreatOptix, we have focused on cloud workload protection from inception,” said Udi Shamir. “The existing EDR solutions are not optimized to address the dynamic and ephemeral nature of modern cloud-native applications that run on containers and Kubernetes. Partnering with Orca, the leader in agentless cloud security, will strengthen an already innovative solution to better address the use cases for deploying an agent for cloud workload protection.”

Upon this integration, Orca Cloud Security Platform customers will be able to immediately deploy and manage the ThreatOptix agent as well as configure policies from the Orca UI. All agent-based runtime telemetry will be fully available within the Orca Unified Data Model to ensure ease-of-use and operation.

“Many partnerships in the cybersecurity ecosystem lack a deep integration strategy. This leads to duct-taped solutions that are inefficient and lack value for their users,” said Gil Geron CPO and co-founder of Orca Security. “We believe this strategic partnership and integration will be transformative for securing the cloud in a purpose-built way to deliver a seamless solution sold under a single SKU. Once integrated, Orca customers will have a seamless experience with the agent acting similarly to a native Orca capability. The Platform will support all cloud environments secured by us today, including highly regulated environments like FedRAMP.”

To learn more about how Orca is focused on securing cloud environments and addressing cloud risks, visit the Orca Blog. Additionally, organizations interested in trialing the Orca Platform can sign up for a free, 30-day cloud risk assessment.

Availability
The integrated solution will be available in the second half of 2023.

About Orca Security
Orca Security is the pioneer of agentless cloud security that is trusted by hundreds of enterprises globally. Orca makes cloud security possible for enterprises moving to and scaling in the cloud with its patented SideScanning™ technology and Unified Data Model. The Orca Cloud Security Platform delivers the world's most comprehensive coverage and visibility of all risks across the cloud. With this continuous first-to-market innovations and expertise, the Orca Cloud Security Platform ensures security teams quickly identify and remediate risks to keep their businesses secure. Connect your first account in minutes: https://orca.security or take the free cloud risk assessment.

About ThreatOptix
ThreatOptix provides peerless server protection architected from the ground-up to defend Linux, with a technology that makes it easy for large enterprises and government agencies to detect, classify and mitigate threats with greater efficacy than any existing offering.

* ESG: The Maturation of Cloud-native Security 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Emily Townsend
fama PR for Orca Security
orca@famapr.com

Kirtee Londhe Mehta
PR for ThreatOptix, Inc.
kirtee@threatoptix.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye